Santiago Gisler,  —

Articles by Santiago Gisler

TXA127 Enters Development Program as Potential Treatment for EB

Constant Pharmaceuticals recently announced plans to begin a development program for TXA127 for the treatment of epidermolysis bullosa (EB). The potential therapy is expected to enter Phase 2 clinical trials in EB patients in 2020. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA)…